First Patient, First Visit (FPFV) in Peru, August 2023
On 28th August 2023, the PAVE Peru feasibility study began recruiting patients. The study will evaluate the use of radical cure with chloroquine and either primaquine (PQ) or tafenoquine (TQ) after G6PD testing in health facilities. In this initial phase in higher-level facilities, such as hospitals, the study aims to enroll the first 50 patients. An interim analysis will then be conducted to determine if the study should move into the next phase, which involves studying the new treatment algorithm in lower-level facilities, such as malaria clinics and health posts.